Simcere Pharmaceutical holds 52.5% equity interest in Simcere Vaxtec subsidiary that expects to resume influenza vaccine production.
Separately, the company also announced the resignation of executive vice president Hong Zhao, effective 1 April 2013.
Simcere Pharmaceutical specializes in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China.